⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7361767 | 0.83 | — | — | |
| SCHEMBL7361575 | 0.71 | — | — | |
| SCHEMBL2572277 | 0.64 | — | — | |
| SCHEMBL26371 | 0.55 | — | — | |
| SCHEMBL6618 | 0.55 | — | — | |
| Lithium Ion SCHEMBL6380312 | 0.52 | — | — | |
| SCHEMBL13277608 | 0.52 | — | — | |
| Hydrochloric Acid SCHEMBL1200019 | 0.52 | — | — | |
| SCHEMBL18760074 | 0.37 | — | — | |
| SCHEMBL65791 | 0.37 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1493 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118285384-A | In-situ fumigation method for controlling mold disease of tomb wall painting | 中国科学院上海有机化学研究所 | 2024-07-05 | — | — | CN | claimed |
| WO-2024140824-A1 | PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-07-04 | — | — | WO | claimed |
| CN-118265702-A | Microbiocidal isonicotinamide derivatives | 先正达农作物保护股份公司 | 2024-06-28 | — | — | CN | claimed |
| EP-4387629-A1 | 6-SUBSTITUTED- AND 6,7-DISUBSTITUTED-7-DEAZAPURINE RIBONUCLEOSIDE ANALOGUES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2024-06-26 | — | — | EP | claimed |
| EP-4353733-A2 | NUCLEOSIDE DERIVATIVE HAVING MULTI-TARGET KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER COMPRISING SAME | Future Medicine Co., Ltd. (KR) | 2024-04-17 | — | — | EP | claimed |
| EP-4332103-A1 | SULFOXIMINE-CONTAINING ATR INHIBITOR COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-03-06 | — | — | EP | claimed |
| CN-117460736-A | Nucleoside derivatives having multi-target phosphorylase inhibitory activity and pharmaceutical compositions for preventing and treating cancer comprising the same | 未来制药有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-117295740-A | ATR inhibitor compounds containing sulfinamide groups | 正大天晴药业集团股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| WO-2023239846-A1 | HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLIXOGEN THERAPEUTICS LTD. (IL) | 2023-08-03 | — | — | US | claimed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | claimed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | claimed |
| EP-1379520-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | claimed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | claimed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | claimed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | claimed |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK SHARP & DOHME LLC | 2002-11-07 | — | — | US | claimed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | claimed |
| US-6147210-A | Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-14 | — | — | US | claimed |
| WO-1998004535-A1 | A PRACTICAL SYNTHESIS OF BENZOXAZINONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-02-05 | — | — | WO | claimed |